麻豆传媒

Vertex Pharmaceuticals put its phase I/II study of the investigational type 1 diabetes treatment VX-880 on following two patient deaths that the company said were unrelated to the study drug.

Merck is looking to develop GLP-1 receptor agonist treatments that do more , the company's CEO said. (Reuters)

Meanwhile, Eli Lilly warned that its popular GLP-1 agent tirzepatide (Mounjaro, Zepbound) shouldn't be used . (The Hill)

Tandem Diabetes announced that its t:slim X2 insulin pump with Control-IQ technology is the to integrate with Abbott's FreeStyle Libre 2 Plus sensor.

Do people after stopping weight loss drugs? A Deutsche Bank survey indicated so. (CNBC)

The reports of alopecia, aspiration, and suicidal ideation in people taking GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide. However, a recent study actually showed a lower suicidal ideation risk with semaglutide compared with non-GLP-1 anti-obesity medications. (CNN)

Rising malpractice premiums are pricing small clinics out of . (KFF Health News)

Bayer said that two phase III trials testing the investigational, for moderate to severe vasomotor symptoms in postmenopausal women met all primary and key secondary endpoints.

Though overall cognition didn't change, people with class II/III obesity who underwent bariatric surgery had a . (Journal of Nutrition, Health & Aging)

Bias in healthcare may be behind misdiagnoses of , which can lead to mismanagement of the disease. (NBC News)

An investigation found that the -- plasticizers used to make plastic more flexible and durable -- remain widespread in food. (Consumer Reports)

Exposure to more green space was linked with significantly in young kids. (JAMA Network Open)

Comment